How it works

Simple Online Telehealth Treatment

Getting started with prescription weight loss medication — GLP-1s like semaglutide are shown to reduce body weight by an average of 14.9% — ketamine therapy, which is non-inferior to ECT for treatment-resistant depression, or mental health treatment has never been easier. Here's exactly how our telehealth process works — simple, fast, 100% online.

  1. 1

    Step 1: Complete Our Online Health Assessment

    Takes just a few minutes. Tell us about your symptoms and health goals from the comfort of your home.

  2. 2

    Step 2: Review by a Licensed Provider

    A board-certified provider reviews your information and determines if treatment is appropriate for you.

  3. 3

    Step 3: Receive Your Prescription

    If approved, your prescription is sent to our partner compounding pharmacy.

  4. 4

    Step 4: Fast Shipping to Your Door

    Your medication is delivered directly to your home with discreet packaging. No pharmacy visits required.

  5. 5

    Step 5: Ongoing Provider Support

    Message your provider with questions or concerns whenever you need follow-up care.

Read next

Learn more before you start.

View all articles

Ready to feel like yourself again?

Start a confidential visit in minutes. Pay only if prescribed.

Scientific References

Peer-reviewed studies (2021 and newer) referenced on this page.

  1. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025.
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
  3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
  4. Bahji A, et al. Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis. 2024.
  5. Long-Term Outcomes in Patients With Treatment-Refractory Depression Receiving Intravenous Ketamine and Intranasal Esketamine. 2025.
  6. Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment-resistant depression. 2024.
  7. Johnson et al. Effectiveness of Combined Oral Minoxidil and Finasteride in Men with Androgenetic Alopecia. 2025.
  8. Abeck D, et al. Patient-reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia. J Cosmet Dermatol. 2024.
  9. Piraccini BM, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia. J Cosmet Dermatol. 2022.
  10. Pyrgidis N, et al. Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. JAMA Network Open. 2021;4(2):e2036337.
  11. Huang Y, et al. Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses. BMJ Open. 2021;11(8):e047396.
  12. Associations between phosphodiesterase type 5 inhibitors and vascular function: a systematic review and meta-analysis of randomized controlled trials. Systematic Reviews. 2025.
Call (786) 868-0920